Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,778.00
Bid: 1,774.00
Ask: 1,774.50
Change: -10.50 (-0.59%)
Spread: 0.50 (0.028%)
Open: 1,796.00
High: 1,808.50
Low: 1,772.50
Prev. Close: 1,788.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

13 Mar 2024 15:48

RNS Number : 7499G
GSK PLC
13 March 2024

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications & CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of 9,000 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.7189

9,000

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications & CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of 4,340 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.7944

4,340

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dylan Jackson

b)

Position/status

PCA of Sally Jackson (SVP, Global Communications & CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of 13,616 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6871

13,616

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dylan Jackson

b)

Position/status

PCA of Sally Jackson (SVP, Global Communications & CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of 2,476 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.7145

2,476

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

e)

Date of the transaction

2024-03-12

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, GSK Global Health

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of 60,000 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.8004

60,000

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2024-03-12

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

7 (partnership shares)

£16.6610

7 (matching shares)

d)

Aggregated information

Aggregated volume Price

14 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Julie Brown

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

8 (partnership shares)

£16.6610

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

8 (partnership shares)

£16.6610

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

7 (partnership shares)

£16.6610

7 (matching shares)

d)

Aggregated information

Aggregated volume Price

14 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

8 (partnership shares)

£16.6610

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

8 (partnership shares)

£16.6610

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Philip Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

8 (partnership shares)

£16.6610

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, Global Health, GSK

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

7 (partnership shares)

£16.6610

7 (matching shares)

d)

Aggregated information

Aggregated volume Price

14 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.6610

7 (partnership shares)

£16.6610

7 (matching shares)

d)

Aggregated information

Aggregated volume Price

14 Ordinary Shares

£16.6610

e)

Date of the transaction

2024-03-11

f)

Place of the transaction

London Stock Exchange (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHSFIFIDELSELD
Date   Source Headline
14th Apr 20204:35 pmRNSDirector/PDMR Shareholding
14th Apr 20204:31 pmRNSDirector/PDMR Shareholding
14th Apr 20203:09 pmRNSDirector/PDMR Shareholding
14th Apr 202012:00 pmRNSSanofi and GSK collaboration to fight COVID-19
9th Apr 202011:52 amRNSAGM - Change of Arrangements
6th Apr 20201:00 pmRNSGSK and Vir Biotechnology enter collaboration
1st Apr 202012:57 pmRNSGSK completes divestment of Horlicks
1st Apr 202011:11 amRNSTotal Voting Rights
30th Mar 20204:06 pmRNSConsumer Healthcare product sales category changes
25th Mar 20204:42 pmRNSSecond Price Monitoring Extn
25th Mar 20204:37 pmRNSPrice Monitoring Extension
24th Mar 20204:40 pmRNSSecond Price Monitoring Extn
24th Mar 20204:35 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSPublication of AGM Notice
20th Mar 20202:00 pmRNSDirectorate Change
18th Mar 202012:20 pmRNSDirector/PDMR Shareholding
13th Mar 20205:24 pmRNSEMTN Prospectus Supplement Update
11th Mar 20205:00 pmRNSDirector/PDMR Shareholding
9th Mar 20204:15 pmRNSDirector/PDMR Shareholding
9th Mar 20207:00 amRNSPublication of GSK 2019 Form 20-F
4th Mar 20202:53 pmRNSAnnual Financial Report
2nd Mar 202011:00 amRNSTotal Voting Rights
21st Feb 20201:00 pmRNSDirector/PDMR Shareholding
20th Feb 20203:30 pmRNSDirector/PDMR Shareholding
20th Feb 20202:00 pmRNSDirector/PDMR Shareholding
20th Feb 20202:00 pmRNSDirector/PDMR Shareholding
19th Feb 20205:25 pmRNSDirector/PDMR Shareholding
19th Feb 20204:35 pmRNSDirector/PDMR Shareholding
19th Feb 20204:28 pmRNSDirector/PDMR Shareholding
19th Feb 20204:24 pmRNSDirector/PDMR Shareholding
19th Feb 20204:17 pmRNSDirector/PDMR Shareholding
12th Feb 20205:05 pmRNSDirector/PDMR Shareholding
11th Feb 20202:15 pmRNSDirector/PDMR Shareholding
11th Feb 20207:00 amRNSTransfer of Treasury Shares
6th Feb 20204:00 pmRNSDirector/PDMR Shareholding
5th Feb 20204:15 pmRNSDirector/PDMR Shareholding
5th Feb 202012:00 pmRNSFinal Results
3rd Feb 20203:15 pmRNSGSK publishes provisional 2020 Dividend Dates
3rd Feb 20209:30 amRNSTotal Voting Rights
15th Jan 20207:00 amRNSDirector/PDMR Shareholding
14th Jan 20204:46 pmRNSDirector/PDMR Shareholding
14th Jan 20204:01 pmRNSDirector/PDMR Shareholding
13th Jan 20206:00 pmRNSDirector/PDMR Shareholding
13th Jan 202011:41 amRNSDirector/PDMR Shareholding
13th Jan 202011:01 amRNSDirector/PDMR Shareholding
13th Jan 202010:34 amRNSDirector/PDMR Shareholding
8th Jan 20204:30 pmRNSGSK publishes provisional 2020 Dividend Dates
8th Jan 20203:11 pmRNSGSK publishes 2020 Dividend Dates
8th Jan 20202:37 pmRNSGSK Announces addition to Corporate Executive Team
2nd Jan 20209:58 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.